Diasorin Spa (OTCMKTS:DSRLF) – Research analysts at Jefferies Group issued their FY2017 earnings per share (EPS) estimates for Diasorin in a report issued on Monday. Jefferies Group analyst P. Welford anticipates that the company will post earnings of $3.53 per share for the year. Jefferies Group also issued estimates for Diasorin’s Q4 2017 earnings at $1.22 EPS, FY2018 earnings at $3.62 EPS, FY2019 earnings at $3.84 EPS, FY2020 earnings at $4.05 EPS and FY2021 earnings at $4.26 EPS.
Separately, Zacks Investment Research cut shares of Diasorin from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 5th.
WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/15/jefferies-group-comments-on-diasorin-spas-fy2017-earnings-dsrlf.html.
Diasorin Company Profile
DiaSorin S.p.A. engages in the development, production, and commercialization of diagnostic tests that are designed for hospital and private testing laboratories for use in various clinical areas in the market of immunodiagnostics and molecular diagnostics. The company offers immunodiagnostics products in the areas of infectious diseases; bone and mineral metabolism; endocrinology, including diabetes, thyroid function, fertility, growth, adrenal function, and gastroenterology; hypertension; oncology; gastrointestinal infections; autoimmunity; and cardiac and brain damages.
Receive News & Ratings for Diasorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diasorin and related companies with MarketBeat.com's FREE daily email newsletter.